So, you know how biotech stocks can sometimes feel like they're moving on pure hope and Phase I data? Well, ImmunityBio Inc. (IBRX) is having a moment powered by something far more tangible: actual sales. A lot of them.
The company's shares are up sharply after it announced financial results that can only be described as explosive. The engine behind this boom is Anktiva, ImmunityBio's lead drug, which is approved in the U.S. and several international markets for a specific, hard-to-treat form of bladder cancer.
Investors have taken notice, pushing the stock up around 55% over the last month. This rally isn't just about a hopeful press release; it's backed by preliminary earnings that smashed expectations and news of several strategic partnerships to launch the drug more broadly.
The 700% Sales Jump
Let's talk numbers, because they're the star of the show. ImmunityBio reported revenue skyrocketed to $38.29 million in the quarter. That's up from just $7.56 million a year ago—a increase of roughly 700%. For context, they also beat the analyst consensus estimate of $37.02 million. Even the loss per share was better than expected, coming in at six cents versus an estimated loss of nine cents.
The driver? Anktiva. The company reported a 750% increase in unit sales volume for the drug. In under two years since its initial FDA approval in 2024, Anktiva has secured regulatory approvals across 33 countries for treating non-muscle invasive bladder cancer. That's a rapid global footprint expansion by any measure.
But ImmunityBio isn't just counting its cash from one indication. The company is actively enrolling patients in clinical trials to test Anktiva against various other cancers, aiming to build it into a broader cancer treatment platform. In a sign of this forward momentum, the company said in January it plans to submit additional information to the FDA following a meeting about using Anktiva for another type of bladder cancer (papillary NMIBC).
It's worth noting that while the broader market has been mixed, the healthcare sector has shown some resilience. This suggests ImmunityBio's gains are largely a company-specific story, not just a rising tide lifting all boats.
What the Charts Are Saying
From a technical perspective, the stock's move has been powerful. It's currently trading about 5.6% above its 20-day simple moving average and 8.4% above its 100-day average, which points to a strong short-term uptrend. Over the past year, shares have climbed significantly and are now much closer to their 52-week highs than their lows.
However, the momentum indicators tell a slightly more nuanced story. The Relative Strength Index (RSI) is sitting right at 50, which is considered neutral—the stock isn't overbought or oversold. Meanwhile, the MACD indicator is slightly below its signal line, hinting at some underlying bearish pressure or caution among traders.
This mix of a strong price trend above key averages but neutral-to-slightly-cautious momentum signals suggests the market is digesting the huge news. Traders are likely identifying key levels to watch: $10 appears as a major resistance point to break through, while $8.50 could serve as important support if the stock pulls back.
At the time of reporting, ImmunityBio shares were up 15.69%, trading at $10.07.
The story here is clear: a biotech company transitioned from a development-stage story to a commercial one, and the early sales results are turning heads. The question now is whether Anktiva's launch trajectory can continue and how quickly its potential in other cancers can become reality.
